about
Lent-On-Plus Lentiviral vectors for conditional expression in human stem cellsSpecific marking of hESCs-derived hematopoietic lineage by WAS-promoter driven lentiviral vectorsAbsence of WASp Enhances Hematopoietic and Megakaryocytic Differentiation in a Human Embryonic Stem Cell Model.Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine familyDendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells.Cecal ligation puncture procedure.Safer vectors for gene therapy of primary immunodeficiencies.The 'Omics' of Amyotrophic Lateral Sclerosis.Generation of a Vero-Based Packaging Cell Line to Produce SV40 Gene Delivery Vectors for Use in Clinical Gene Therapy Studies.Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.Efficient lentiviral transduction of Herpesvirus saimiri immortalized T cells as a model for gene therapy in primary immunodeficiencies.Mesenchymal stromal cells express GARP/LRRC32 on their surface: effects on their biology and immunomodulatory capacityIn vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.Was cDNA sequences modulate transgene expression of was promoter-driven lentiviral vectors.Viral gene delivery vectors: the next generation medicines for immune-related diseases
P50
Q28595666-E97F3B9B-5B36-47D0-A1FA-51CE7178ADF6Q28728465-80AD8773-90C4-4F47-97BF-43A9E0AFCCA1Q33427058-AC8565B8-5A4B-4D62-836C-368ED9B66CEBQ33683288-CDBEF5CB-C5B5-472C-8F4B-18AD22A7C4CFQ33931602-C92F7D92-D6B6-455E-AA58-E7ED91AF2772Q34759410-F732A21C-C879-40F2-AFBF-3BBFC986C0C0Q35591443-EFD4B559-804A-48E6-A976-B0798C6E8A39Q35921197-820E3843-C1FB-4314-BE00-75B1A98D33A6Q37522521-B6E2066D-C2C5-415D-9AAD-1CFC03C421BEQ38675629-B4F8BB11-8E0E-495F-939E-0F61B3D397CAQ38695385-DFEE4D91-0C8C-4729-87D7-359E80F3065BQ40017995-AB040DB2-BE9C-40EB-9457-61946022EE81Q40577040-5653404C-AA26-4EA8-A830-2D462CFFD402Q41817619-450497A5-5DB3-4823-8BF3-19210C8AB139Q45876405-034DFBEE-92D1-495C-975C-721CDEAB8F74Q45887173-747C2CAB-244C-4990-88F0-400C891C7202Q94935813-A24440D1-0F16-49C2-A335-94747382615B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Miguel G Toscano
@ast
Miguel G Toscano
@en
Miguel G Toscano
@es
Miguel G Toscano
@nl
Miguel G Toscano
@sl
type
label
Miguel G Toscano
@ast
Miguel G Toscano
@en
Miguel G Toscano
@es
Miguel G Toscano
@nl
Miguel G Toscano
@sl
prefLabel
Miguel G Toscano
@ast
Miguel G Toscano
@en
Miguel G Toscano
@es
Miguel G Toscano
@nl
Miguel G Toscano
@sl
P1053
I-1053-2015
P106
P21
P2798
P31
P3829
P496
0000-0002-6384-3123